

éääíñéíé Àññíòéåòéåé Ýóíéäðääéíäðåòèñóíá (N.D.Schl ðññííääò 1989).

Íðè èññéääííááíéè èìíóííííí ñòåòóñà (ÈÑ) íäðÿå ñ íáúáíðéíÿòííè ïíéåçàðòéÿíè ñ ðåñ-+åòíí éíéè-+áñðåàéåéííòéòíá, íáéòòííòééíá, +èñéå Ò- è Á-èèííóíòéòíá, íáíè èçó-+åéåñú Ò-ííòéèè-+áñéÿ ñòòóéòóðå ééåòíé èìíóíííí ñè-ñòáíú. Ííéò-+áííúä ðåçóóòòú áíéúíúò ÍÈÑ è ÑÑ ñðåáíéåääèñú ñ ïíéåçàðòéÿíè éííòòíéúííé äòòííú 15 çáíðíáúò èèò (áåç ÈÑ) ñííòéåòñòòò-þúáé áíçðåñòííé èåòääíòéè.

Äéÿ èçó-+áíéÿ ñíñòíÿíéÿ ééåòí-íííí èìíó-íéòåòà è àíííòíçà áðåè 15 íè èòíáè èç éíéòå-áíé ááíú á íðíáéðéò ñ äääíðéííí (èç ðåñ-+åòà 15 - 20 Å/íé èòíáè). Èåéííòéòú íäðéòåðé-+áñéíé èòíáè áíúääéÿ è íñåääáíéåí á 3% ðåñ-+åòåíá ðå-èåòéíá. Çåòáí íðíáíéèèñú 3-èòåòíáÿ íòííúèèòá òíñòåòíí-ñíéåáíú áóòåòíí (pH 7,4). Á-èè-áíí ñéò-+åå ííåñ-èòúääèè íðíóáíò ïíéåèòéè èéåòíé, éíòíòúé ñíñòééÿ, éåé íðåéèí, 2-5%. Áíáèèç ééåòí-ííé äèååèè áíííéíÿñÿ íáñéíé-èèèè íäòíááíè: ñ ííííúþ áèòééúííé íéðåñéè òðéíáííáúí ñéíéí, àòåéèåè äèðééíáúí íðáí-æåáíú è ÿòéèèòíí áðííéåíí. Ííðåääéåíéè íðí-òáíòà ïíéåèòéè ééåòíé (1) íðíáíéèíñú íà éí-áðòéòííááííí íèèòííéíá « Opton » (Áíéèáí-äéÿ) íðè óåéèè-+áíéè 12020 è íðè óåéèè-+áíéè 100100 á óéúòåòéíéèòíáíí ñååòá (2), íðè ÿòíí íéðåèåííú èéåòéè ÿòéèèòíí áðííéåíí, éíòí-òúé, ÿéÿÿñú èèòíðåñòáíòíú éðåñéòéåí, ñáÿçúääåòñÿ ñ ÁÍÈ ïíéåèòéè ééåòíé, íòáíé-ääèèñú èåé íäòòáíú. Äéÿ èìíóííóáííòéèè-òíááíéÿ èñííéúçíááéè ïííééííééúíú áíòé-òåèà (ÍÈÀ) íðíéçáííñòåè ÍÍ «Íååéñí-íéèòð». Íðè ïíñòáííéåè íáðÿííé èåéòéè èìíóííéòíðåñòáíòéè èñííéúçíááéè áåðáíúþ áíòèñúáíòíòéò íðíòéè èìíóííééííáòééíá íúòé, íå-+áíòþ FTTC («Íååéñííéèòð»), íðå-áåðéòééúíí íáñéíéúéí ðåç äåñíðåéòíááííóþ éåééíòéòáíè +éííáéè äéÿ èñéþ-+áíéÿ íáñíá-òéòé-+áñéíá ñáÿçúääéÿ.

Íåòíáíí íáðÿííé èåéòéè ïíååòóííòííé èìíóííéòéþíðåñòáíòéè ïíéò-+áííúä òèèñéòí-ääííúä íðíáú áíáèèçéòíáéè íà èàçðííí íðí-òí-ííí òéòíòéòíðéíáòéè FACS vantage (« Becton Dickinson » ÑØÀ) è ïíðåääéÿ èÿéñí-ðåññéþ áíòéèåíá CD3 çðéúò Ò-èéåòíé, áíòéè-íá CD4 Ò-òééíáòíá, áíòéèåíá CD8 Ò-ñóíðåññí-òíá, áíòéèåíá CD16 áññòåòáííú èèèèòíá, áí-òéèåíá CD25 íðíòéè ðåòáíòíðå éíòéèéééíá-2, áíòéèåíá CD 71 (ðåòáíòíð òðáíñòåòéíá), áí-òéèåíá CD11b (Í-òáíú éíòéèééíá CD11b/18C3b+ðåòáíòíð 3 éíííííáíòàéííéåí áíòé) CD 50 (ííéèéòéèèçéè ICAM 3), àòåéèåè Fæ-áíòéèåíá, ïíñðåääóþúèè àíííòíç (CD 95). Èéè-

òéþ èìíóííéòéþíðåñòáíòéè ñòåéèèè ñéåòóþ-úèí íáðåçíí: ïí 400 000 ééåòíé ñ áíåååáíéåí íáúåáí íáúåíá áí 200 íéè òíñòåòíí-ñíéåáíúí áóòåòíí ñ àçéáíí íàòòéÿ òáíòéèòóéèòíáéèè íà òíéíáò á òå-+áíéå 10 íéí íðè 1000 íá/íéí, ñ-íáðíáòåíò óåéÿèè, à ññåáíé ðåññíáíáéèòíáéèè àòíí æáíáúáíá ññåáíú è áíáæéÿèè 20 íéèñí-íçäòñòåòþúèò íéÀÒ, éíéóååòéþ áåèè 30 íéí íðè +4Ñ, ïíñéå-+æíí äåääåú íòíúääèè òíé æå ñðåáíé íà òáíòéèòóçá íðè 1000 íá/íéí íðè +4Ñ á òå-+áíéå 10 íéí. Ñáíò è áíáèèç äääíúò ññòå-ñçéÿèè ïí íðíáòáííá Lysys II («Becton Dickinson», ÑØÀ) ñ èñííéúçíááéèè áééòíá «èèòíòéèòú» è «äðáíòéèòéòú» íà ññííááíéè èííáéíáòéè ñåòóðåññáÿíéÿ è ðåçí áðå ééåòíé.

Ðåçóéúòåòú è íáñòæåáíéå

Íðéçíáéèè ïíáúòáíííé ÿéòíé-+áñéíé æéòé-ííòé íéíéäðåè æééòáí-éíá á èèå ÿíéçíáíá æééòáí-éíáíé ÿéñòðåññéòíéèè áññíéèò äðåå-òéè (+áñòé > 10 á +áñ., íäòííé è /èèè äòòíí-áíé) íáíè áúèè çðåääéñòðéòíááíú òíéúéíó áíéúíúò ÍÈÑ, íðè ÍÈÌ +áúå (42%), æí íðè ÍÑ (25%). Ýíéçíáú òðáíçéòíðííé èòáíé-+áñ-éíé ááíðåññé ñæíáíòðà ST ðåññéòðéòíáéèñú ó 21% áñåò íåéþæåíúò áíéúíúò ÍÈÑ (44%) è ÑÑ(30%); +áúå íðè ÍÑ (55%), çæå - íðè ÍÈÌ (32%) è ÑÑ (30%). Ñéñòíéè-+áñéÿ òóí-éòéÿ èæí íáí æééòáí-éå ó ïíååéÿþúæí +èñ-èà íåéþæåíúò áíéúíúò ÍÈÑ è ÑÑ áúèåñí-òðáíáá: ÓÀ ÈÈ 45% ïíðåääéÿèñú ó 87% áíéú-íúò: áíéåå áññíéèè áå çíá-+áíéÿ áúèè ó áíéúíúò ÑÑ, ïí ñðåáíáíéþ ñ áíéúíúèè ÍÈÑ. Ñíéæáíéå ÓÀ ÈÈ < 45% áúÿéåáíí ó 7 áíéúíúò (14%), 4 èç éíòíòúò - áíéúíúà ÍÈÌ.

Íðíáåääáíúé áíáèèç ÁÐÑ áúÿéèè íðíáíí-òé-+áñéè íåéèääííòéÿòíú èçíáíáíéÿ íáúåè ÁÐÑ, áúðåæáííúà á òíé èèè éííé ñòåíáíé, èæé ó áíéúíúò ÍÈÑ, òåé è ÑÑ. Çíá-+áíéÿ ïíéåçàðòééè SDNN, TI è RMSSD áññòíáðòíí (p<0,05) íéæåó áíéúíúò ÍÈÌ ïí ñðåáíáíéþ ñ áíéúíúèè ÍÑ è ÑÑ. Ó áíéúèéíñçåáíéúíúò ÍÈÑ íòíá-+éíñú òíäðáííá ñíéæáíéè ïíéåçàðòééè SDNN (50 ññ< SDNN < 100 ññ. 72%), p < 0,05 è TI (< 20, 59%) ïí ñðåáíáíéþ ñ áíéúíúèè ÑÑ (40%).

Íðè ÿòíí, óíáðáííá ñíéæáíéè íáííáòáí-áí-íí ááóò ïíéåçàðòééè - SDNN è TI íåéþæéíñú ó ïíååéÿþúåáí +èñéè áíéúíúò ÍÈÌ (74%), çæå - íðè ÍÑ (55) è ÑÑ (40%) ñííçäòñòåòáíí.

Çíá-+èòééúííá ñíéæáíéè íáííáòáíáíí ááóò ïíéåçàðòééè - SDNN (< 50 ññ) è TI (< 15), íòí-ñÿúääñÿ è íåçåéñéíúí òåéòíðåí áññíéíáí òèñéèà çåçåòéÿ ÁÑÑ, íòíá-+éíñú òíéúéí íðè ÍÈÌ è ÍÑ [1-3, 11, 35, 36]. Íðè ñíéèòééúííí áíáèèçáó áíéúíúò ñ ÍÈÑ è ÑÑ òåéèèòéòí-+é-

26. Companero M.R., del-Pozo M.A., Arroyo A.G., Sanchez Mateos P. ICAM-3 interacts with IFA-1 and regulates the IFA-1/ ICAM-1 celladhesion pathway. *J Cell Biol.* 1993; v.123 ,N 4. p .1007-16.

27. Bossowska A., Kiersnowska-Rogowska B., Bossowski A. Assessment of serum levels of adhesion molecules (sICAM-1, sVCAM-1, sE-selectin) in stable and unstable angina and acute myocardial infarction. *Przegl Lek.* 2003; 60(7):445-50.

28. Lemos J.A., Hennekens C.H., Ricker P.M. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. *J Am Coll Cardiol.* 2000; Aug; 36(2):423 - 6.

29. Biasucci L.M., Liuzzo G., Grillo R.L. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. *Circulation* 1999;99:855 - 860.

30. Cassie S., Materson M.F. Ischemia/reperfusion induces the recruitment of leukocytes from whole blood under flow conditions. *Free Radic Biol Med.* 2004; May; 36 (9):1102-11.

31. Soeki T, Tamura Y, Shinchara H. Increased soluble platelet/endothelial cell adhesion molecule -1 in the early stages of acute coronary syndromes. *Int J Cardiol.* 2003 ; Aug; 90(2-3):261-8.

32. Lucchesi D.R., Wems S.M., Fantone J.C. The role of neutrophil and freeradical in ischemic myocardial injury *J Mol cell cardiol.* 1989; 21:1241-1251.

33. Íièñááá Á.Ñ., Ááðúóíèèíá À.Þ., Óáðáúáíéí N.Í. è níááð. Áèèýíèá ððèíáðáçèèéíá íà áíííðíç è èííóííéí-æè-áñèèèè óáííðèí ó áíèúíúð ñ íñðóúí èíðáðèóíí íè-íèáðáá è çáñóíéííé níáðáá+ííé íááíñðáðí+ííñðúþ. Þáð-æèíéíæý. 1998; 6 :40 - 43.

34. Garlachs C.D, Eskafi S, Cicha I. Delay of neutrophil apoptosis in acute coronary syndromes. *J Leukoc. Biol.* 2004; May;75 (5):828-35.

35. Kèýíer R.E., Míèñ J.P., Bígíer T. et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *J Am Cardiol.* 1987; 59:256-262.

36. Meinerz T, Zehender M. Risk assessment in coronary heart disease: ventricular arrhythmias, myocardial ischemia and sudden cardiac death. *Z-Kardiol.* 1998; 87 Suppl. 2:106-15

37. Molgaard H., Sorensen K. Attenuated 24-hour heart rate variability in apparently healthy subjects, subsequently suffering sudden cardiac death. *Clin. Auton. Res.* 1991; 22:223-237.

38. Málíani A, Lombardi F, Pagani M. Power spectral analysis of cardiovascular variability in patients at risk for sudden cardiac death. *J Cardiovasc. Electrophysiol.* 1994;23:274-286.

39. Seidí K, Rameken M., Guhl K. et al. Value of classic and new risk indicators for identifying patients at high mortality risk: Results of the post-infarct risk stratification study (PIRS). Supplement to *J of the American College of Card.* 2000; Feb.Vol. 35(2) A:145.